Citations

Clear

1446 citation(s) found for "Howard, F".

Appropriate Telemedicine Utilization in Spine Surgery
Iyer, Sravisht, Bovonratwet, Patawut, Samartzis, Dino, Schoenfeld, Andrew J., An, Howard S., Awwad, Waleed, Blumenthal, Scott L., Cheung, Jason P.Y., Derman, Peter B., El-Sharkawi, Mohammad, Freedman, Brett A., Hartl, Roger, Kang, James D., Kim, Han Jo, Louie, Philip K., Ludwig, Steven C., Neva, Marko H., Pham, Martin H., Phillips, Frank M., Qureshi, Sheeraz A., Radcliff, Kris E., Riew, K. Daniel, Sandhu, Harvinder S., Sciubba, Daniel M., Sethi, Rajiv K., Valacco, Marcelo, Zaidi, Hasan A., Zygourakis, Corinna C., Makhni, Melvin C., Iyer, Sravisht, Bovonratwet, Patawut, Samartzis, Dino , Schoenfeld, Andrew J., An, Howard S., Awwad, Waleed Mohammad , Blumenthal, Scott L., Cheung, Jason P.Y., Derman, Peter B., El-Sharkawi, Mohammad Mostafa , Freedman, Brett A., Hartl, Roger, Kang, James D., Kim, Han Jo, Louie, Philip K., Ludwig, Steven C., Neva, Marko H., Pham, Martin H., Phillips, Frank M., Qureshi, Sheeraz A., Radcliff, Kris E., Riew, K. Daniel, Sandhu, Harvinder S., Sciubba, Daniel M., Sethi, Rajiv K., Valacco, Marcelo, Zaidi, Hasan A., Zygourakis, Corinna C., Makhni, Melvin C.

Mayo Clinic

Spine | February 7, 2022 | Volume: 47 | Issue: 8 | Pages: 583-590

10.1097/brs.0000000000004339 | PMID 35125460 Get It

Study Design. Delphi expert panel consensus. Objective. To obtain expert consensus on best practices for appropriate telemedicine utilization in spine surgery. Summary of Background Data. Several studies have shown high patient satisfaction associated with telemedicine during the COVID-19 peak pandemic period as well as after easing of restrictions. As this technology will most likely continue to be employed, there is a need to define appropriate utilization. Methods. An expert panel consisting of 27 spine surgeons from various countries was assembled in February 2021. A two-round consensus-based Delphi method was used to generate consensus statements on various aspects of telemedicine (separated as video visits or audio visits) including themes, such as patient location and impact of patient diagnosis, on assessment of new patients. Topics with ≥75% agreement were categorized as having achieved a consensus. Results. The expert panel reviewed a total of 59 statements. Of these, 32 achieved consensus. The panel had consensus that video visits could be utilized regardless of patient location and that video visits are appropriate for evaluating as well as indicating for surgery multiple common spine pathologies, such as lumbar stenosis, lumbar radiculopathy, and cervical radiculopathy. Finally, the panel had consensus that video visits could be appropriate for a variety of visit types including early, midterm, longer term postoperative follow-up, follow-up for imaging review, and follow-up after an intervention (i.e., physical therapy, injection). Conclusion. Although telemedicine was initially introduced out of necessity, this technology most likely will remain due to evidence of high patient satisfaction and significant cost savings. This study was able to provide a framework for appropriate telemedicine utilization in spine surgery from a panel of experts. However, several questions remain for future research, such as whether or not an in-person consultation is necessary prior to surgery and which physical exam maneuvers are appropriate for telemedicine. Level of Evidence: 4
Prkci Regulates Autophagy and Pancreatic Tumorigenesis in Mice
Inman, Kristin S. , Buzhardt, Michele Scotti , Leitges, Michael , Krishna, Murli , Fields, Alan P. , Murray, Nicole R. , Scotti Buzhardt, Michele L , Leitges, Michael , Crawford, Howard C, Liu, Yi Sha , Crawford, Howard C.

Mayo Clinic

Cancers | February 4, 2022 | Volume: 14 | Issue: 3 | Pages: 796

10.3390/cancers14030796 | PMID 35159064 Get It

Protein kinase C iota (PKCι) functions as a bonafide human oncogene in lung and ovarian cancer and is required for KrasG12D-mediated lung cancer initiation and progression. PKCι expression is required for pancreatic cancer cell growth and maintenance of the transformed phenotype; however, nothing is known about the role of PKCι in pancreas development or pancreatic tumorigenesis. In this study, we investigated the effect of pancreas-specific ablation of PKCι expression on pancreatic cellular homeostasis, susceptibility to pancreatitis, and KrasG12D-mediated pancreatic cancer development. Knockout of pancreatic Prkci significantly increased pancreatic immune cell infiltration, acinar cell DNA damage, and apoptosis, but reduced sensitivity to caerulein-induced pancreatitis. Prkci-ablated pancreatic acinar cells exhibited P62 aggregation and a loss of autophagic vesicles. Loss of pancreatic Prkci promoted KrasG12D-mediated pancreatic intraepithelial neoplasia formation but blocked progression to adenocarcinoma, consistent with disruption of autophagy. Our results reveal a novel promotive role for PKCι in pancreatic epithelial cell autophagy and pancreatic cancer progression.
Diagnostic value of plasma P‐tau217 in frontotemporal dementia spectrum disorders
Heuer, Hilary W. , Toller, Gianina , Thijssen, Elisabeth H. , Proctor, Nicholas K. , Forsberg, Leah K. , Brushaber, Danielle , Ramos, Eliana Marisa , Coppola, Giovanni , Bordelon, Yvette , Dickerson, Brad C., Fagan, Anne M. , Fields, Julie A. , Foroud, Tatiana M., Galasko, Doug, Gavrilova, Ralitza H. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Graff‐Radford, Jonathan , Grant, Ian , Huey, Edward D. , Kornak, John , Ljubenkov, Peter A. , Lucente, Diane , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Miyagawa, Toji , Onyike, Chiadi U. , Pedraza, Otto , Petrucelli, Leonard , Rademakers, Rosa , Rankin, Katherine P. , Rascovsky, Katya, Ritter, Aaron, Savica, Rodolfo , Staffaroni, Adam M. , Trataglia, Maria Carmela, Weıntraub, Sandra , Rosen, Howard J. , Boxer, Adam L. , Rojas, Julio C. , VandeVrede, Lawren , Appleby, Brian S. , Botha, Hugo , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Fong, Jamie , Goldman, Jill , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Irwin, David J. , Jones, David T. , Kantarci, Kejal , Knopman, David S. , Kremers, Walter K. , Lapid, Maria I. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , McMillan, Corey T. , Miller, Bruce L. , Pascual, Belén , Rexach, Jessica E. , Roberson, Erik D. , Seeley, William W. , Toga, Arthur W. , Wong, Bonnie , Wszołek, Zbigniew K. , Dage, Jeffrey L. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.055763 Get It

AbstractBackgroundFrontotemporal dementia spectrum disorders (FTD) display complex neuropathological substrates and poor clinicopathological correlations, which hinders therapy development. Plasma P‐tau217 is an emerging tool to screen for Alzheimer’s disease (AD) pathology and may have diagnostic value in FTD.MethodPlasma P‐tau217 was measured cross‐sectionally by electrochemiluminescence in FTD patients referred to ALLFTD from ARTFL (n = 628, 45.7% female, median age 66 ± 12 years). P‐tau217 differences by baseline phenotype, disease severity and genotype were determined with non‐parametric tests and general linear models. Associations between P‐tau217 and measures of disease severity and neuropsychological performance were determined with linear regressions corrected for age, sex, phenotype and APOE.ResultThe sample included 33% behavioral variant FTD, 23.6% primary progressive aphasia (PPA), 28.5% atypical parkinsonism, 1.6% amnestic dementia (AmDem), 2.8% FTD/motoneuron disease, 3% mild cognitive/behavioral impairment and 7.5% healthy controls. Only 1.6% carried FTD‐causing mutations. P‐tau217 was not related to age (r = 0.034, 95%CI ‐0.03 – 0.12, p = 0.4). Compared to controls (0.18 ± 0.07 pg/mL), P‐tau217 was elevated only in AmDem (0.58 ± 0.9 pg/mL, p = 0.001) and logopenic PPA (lvPPA, 0.71 ± 0.62 pg/mL p < 0.001). P‐tau217 ≥ 0.42 pg/mL effectively discriminated AmDem and lvPPA from all other phenotypes (AUC 0.87, 95%CI 0.77 – 0.96, p = 0.001, 77% sensitivity, 92% specificity). AmDem (60%) and lvPPA (91.7%) had the highest prevalence of high (≥ 0.42 pg/mL) P‐tau217, and the highest prevalence of APOE4 (AmDem 40%, lvPPA 63.6%). APOE4 carriers (0.23 ± 0.22 pg/mL) had higher P‐tau217, than non‐carriers (0.19 ± 0.09 pg/mL), regardless of phenotype (APOE effect p = .002, APOE x phenotype, p = 0.44). P‐tau217 was associated with worse clinical severity, mood, memory and executive function, but not with worse motor symptoms or social cognition.ConclusionWhen FTD is suspected, high plasma P‐tau217 is strongly associated with amnestic dementia and logopenic PPA phenotypes. Pending completion of ongoing neuropathological, CSF and molecular neuroimaging analyses, the data support the use of plasma P‐tau217 to identify atypical AD as a cause or AD as a co‐pathology contributing to FTD clinical presentation.
Presymptomatic and symptomatic MAPT mutation carriers feature functional connectivity alterations
Zhang, Liwen , Flagan, Taru , Chu, Stephanie A. , Häkkinen, Suvi , Brown, Jesse A. , Mandelli, Maria Luisa , Tempini, Maria Luisa Gorno , Dickerson, Brad C., Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Huey, Edward D. , Karydas, Anna M., Kaufer, Daniel , Mackenzie, Ian R. , Mendez, Mario F. , Onyike, Chiadi U. , Ramos, Eliana Marisa , Trataglia, Maria Carmela, Weıntraub, Sandra , Forsberg, Leah K. , Heuer, Hilary W. , Boxer, Adam L. , Rosen, Howard J. , Lee, Suzee E. , Consortia, ARTFL/LEFFTDS, Lee, Alex J. , Pasquini, Lorenzo , Appleby, Brian S. , Domoto‐Reilly, Kimiko , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Kantarci, Kejal , Knopman, David S. , Litvan, Irene , Roberson, Erik D. , Toga, Arthur W. , Boeve, Bradley F. , Miller, Bruce L. , Seeley, William W. , Consortia, ARTFL/LEFFTDS

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.054128 Get It

AbstractBackgroundClinical trials for tauopathies require novel biomarkers for disease detection and monitoring. One previous study found functional connectivity (FC) alterations in presymptomatic (preSx) MAPT mutation carriers (Whitwell et al., 2011), yet studies have not examined FC networks along the MAPT disease continuum. We hypothesized that both symptomatic (Sx) and preSx MAPT mutation carriers would show FC alterations compared to healthy controls (HC).MethodLeveraging task‐free fMRI data from the UCSF Memory and Aging Center and the ARTFL/LEFFTDS Consortia (Boeve et al., 2019), we compared 14 Sx and 33 preSx to 80 HC to characterize their FC profiles. Using a seed‐based approach, we studied FC within networks associated with different MAPT clinical syndromes (i.e., salience network [SN] for behavioral variant frontotemporal dementia, default mode network [DMN] for Alzheimer’s‐like amnestic syndrome, corticobasal syndrome [CBS] and progressive supranuclear palsy [PSP] networks). Complementing the seed‐based approach, we next calculated whole‐brain intra‐/inter‐network FC matrices for 14 networks (Brown et al., 2019), and applied K‐means clustering to assess whether preSx displayed heterogeneous connectivity profiles. ComBat was applied to harmonize multi‐site imaging data (Fortin et al., 2017, 2018). Thresholding was set at a joint height and extent threshold of p<0.05 (uncorrected) with age, sex, education and handedness as nuisance covariates.ResultCompared to HC, Sx featured disrupted FC within key hubs of all four networks, and regions of cerebellar and pontine hyperconnectivity within CBS and PSP networks. As seen in Sx vs. HC, preSx had similar anatomical patterns of SN/CBS network hypoconnectivity and CBS/PSP network hyperconnectivity vs. HC. In contrast to Sx, who had DMN disruption, preSx showed DMN hyperconnectivity vs. HC.Whole‐brain analyses revealed that Sx had disrupted intra‐/inter‐network FC in networks involving the insula/anterior temporal lobe. Clustering analysis identified two preSx subgroups. Compared to HC, preSx1 principally had disrupted FC across networks including those disrupted in Sx, whereas preSx2 mainly demonstrated hyperconnectivity.ConclusionSx and preSx both demonstrated robust FC alterations. Future studies will investigate whether the preSx subgroup whose whole‐brain FC was similar to Sx in that it showed principally FC disruption may be at greater risk for imminent symptom conversion and/or neurodegeneration.
Complement and NfL associations with brain structure and functional connectivity alterations in presymptomatic and symptomatic GRN mutation carriers
Flagan, Taru , Chu, Stephanie A. , Häkkinen, Suvi , McFall, David , Heller, Carolin , Brown, Jesse A. , Lee, Alex J. , Mandelli, Maria Luisa , Gorno‐Tempini, Marilu, Dickerson, Brad C., Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Huey, Edward D. , Karydas, Anna M., Kaufer, Daniel , Mackenzie, Ian R. , Mendez, Mario F. , Onyike, Chiadi U. , Petrucelli, Leonard , Ramos, Eliana Marisa , Weıntraub, Sandra , Forsberg, Leah K. , Heuer, Hilary W. , Boxer, Adam L. , Rosen, Howard J. , Lee, Suzee E. , Consortia, ARTFL/LEFFTDS, Rohrer, Jonathan D. , Pasquini, Lorenzo , Appleby, Brian S. , Domoto‐Reilly, Kimiko , Foroud, Tatiana , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Kantarci, Kejal , Knopman, David S. , Litvan, Irene , Roberson, Erik D. , Rojas, Julio C. , Tartaglia, Maria Carmela , Toga, Arthur W. , Boeve, Bradley F. , Miller, Bruce L. , Moreno, Fermín , Seeley, William W. , Consortia, ARTFL/LEFFTDS

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.050737 Get It

AbstractBackgroundProgranulin (GRN) mutations cause autosomal dominant frontotemporal lobar degeneration. Clinical trials for GRN‐targeted therapies are underway, yet reliable biomarkers to predict onset and track disease progression remain elusive. Task‐free functional MRI (tf‐fMRI) connectivity may be more sensitive than structural measures for detecting presymptomatic changes (Dopper, 2014; Premi, 2016). Presymptomatic GRN feature tf‐fMRI hyperconnectivity that is more pronounced in older carriers presumably closer to symptom onset, suggesting hyperconnectivity may be a harbinger of disease (Lee, 2019). To aid the interpretation of hyperconnectivity, we explored relationships of structural and tf‐fMRI measures with candidate fluid biomarkers for GRN: CSF complement proteins C3b and C1q, which drive neurodegeneration in GRN ‐/‐ mice (Lui, 2016) and plasma neurofilament light chain (NfL), a marker of axonal injury.MethodWe studied 20 symptomatic GRN (Sx), 39 presymptomatic GRN (preSx), and 67 healthy‐controls (HC). Cross‐sectional CSF C3b, C1q, and plasma NfL concentrations were compared between groups. Correlations controlling for age assessed relationships between fluid biomarkers and symptom severity (CDR®+NACC‐FTLD box score). Voxelwise multiple regression models examined interactions between fluid biomarkers and gene status on grey matter probability maps (GM) and voxelwise tf‐fMRI whole‐brain weighted degree (WBD) maps.ResultComplement concentrations were similar between Sx, preSx, and HC. Across all GRN, C3b concentrations increased with symptom severity (r=0.34, p=0.04). In Sx, but not preSx, higher C3b was associated with increased WBD in medial‐frontal regions, left insula, and thalamus compared to HC. Sx had higher NfL concentrations compared to preSx and HC. Across all GRN and in Sx, higher NfL was associated with greater symptom severity (r=0.60, p<0.001; r=0.72, p<0.001). In Sx, higher NfL was associated with lower GM in precuneus and bilateral frontoinsular cortices, but not WBD, compared to HC. In preSx, higher NfL was associated with increased WBD in thalamus and right temporal regions, but not GM, compared to HC.ConclusionC3b and NfL concentrations correlated with symptom severity. C3b concentrations were associated with tf‐fMRI connectivity alterations in Sx while NfL concentrations were associated with connectivity alterations in preSx. Longitudinal studies are needed to determine temporal relationships between altered connectivity, atrophy, complement, NfL rise, and symptom onset.
Clinical value of CSF tau, p‐tau181, neurogranin and neurofilaments in familial frontotemporal lobar degeneration
Heuer, Hilary W. , Chen, Weiping , Czerkowicz, Julie, Graham, Danielle , Forsberg, Leah K. , Brushaber, Danielle , Ramos, Eliana Marisa , Coppolla, Giovanni, Bordelon, Yvette , Dickerson, Brad C., Fagan, Anne M. , Fields, Julie A. , Galasko, Doug, Gavrilova, Ralitza H. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Graff‐Radford, Jonathan , Grant, Ian , Huey, Edward D. , Kornak, John , Ljubenkov, Peter A. , Lucente, Diane , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Miyagawa, Toji , Onyike, Chiadi U. , Pedraza, Otto , Petrucelli, Leonard , Rademakers, Rosa , Rankin, Katherine P. , Rascovsky, Katya, Ritter, Aaron, Savica, Rodolfo , Staffaroni, Adam M. , Toga, Arthur W. , Weıntraub, Sandra , Rosen, Howard J. , Boxer, Adam L. , Rojas, Julio C. , Appleby, Brian S. , Botha, Hugo , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Fong, Jamie , Foroud, Tatiana , Goldman, Jill , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Irwin, David J. , Jones, David T. , Kantarci, Kejal , Knopman, David S. , Kremers, Walter K. , Lapid, Maria I. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , McMillan, Corey T. , Miller, Bruce L. , Pascual, Belén , Rexach, Jessica E. , Roberson, Erik D. , Seeley, William W. , Tartaglia, Maria Carmela , Wong, Bonnie , Wszołek, Zbigniew K. , VandeVrede, Lawren , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.052993 Get It

AbstractBackgroundBlood neurofilament light chain (NfL) is a robust predictor of phenoconversion in familial frontotemporal lobar degeneration (fFTLD). The comparative value of CSF NfL and other CSF markers of degeneration in fFTLD remains unexplored.MethodFLTD‐causing mutation carriers were recruited through ALLFTD (n = 113, 56.6% female, mean age 48.1 ± 13 years; 29 C9orf72, 16 GRN, 34 MAPT, 34 mutation non‐carriers) and prospectively evaluated for 3 years. Baseline CSF was analyzed for NfL, phosphorylated neurofilament heavy chain (p‐NfH), tau, phosphorylated tau181 (p‐tau) and neurogranin using fit‐for‐purpose immunoassays. Mixed effect linear models, with random slopes, corrected for age, sex, genotype and total intracranial volume related CSF biomarkers to longitudinal clinical variables.ResultNfL (β = 0.64, p < 0.001), p‐NfH (β = 0.68, p < 0.001) and tau (β = 0.46, p < 0.001) correlated with age. There were no differences in biomarker concentrations by phenotype or severity, except for higher NfL and p‐NfH in full phenotype, compared to prodromal disease and asymptomatic carriers. Low neurogranin (β = ‐0.39, p < 0.001), low p‐tau (β = ‐0.33, p < 0.001) and high NfL (β = 0.42, p < 0.001) correlated with worse baseline disease severity measured by the CDR® Dementia Staging Instrument plus behavior and language domains from the National Alzheimer’s Disease Coordinating Center FTLD module sum of boxes (CDR®+NACC‐FTLDsb), and with other measures of global cognition, instrumental and daily function, and frontal and temporal brain volumes. Regardless of genotype, the predicted annualized rate of CDR®+NACC‐FTLDsb score worsenings per higher baseline CSF biomarker Log pg/mL were tau: 3.0 ± 0.2, NfL: 2.8 ± 0.2 and p‐NfH: 2.8 ± 0.2. High tau, NfL and p‐NfH also predicted worsening in other measures of global cognition and instrumental and daily function. Neurogranin and p‐tau did not predict clinical decline.ConclusionCSF tau, p‐tau, neurogranin, NfL and p‐NfH reflect important aspects of disease severity in fFTLD. In contrast to Alzheimer’s disease, low p‐tau and neurogranin are inversely related to clinical severity, which suggests a distinctive pathophysiological process and has implications for therapeutic development. CSF NfL, p‐NfH and tau have strong prognostic value in fFTLD.
Demographic and psychosocial factors associated with the decision to learn mutation status in familial frontotemporal dementia and the impact of disclosure on mood
Bajorek, Lynn, Kiekhofer, Rachel, Hall, Matthew J. , Taylor, Joanne, Lucente, Diane , Brushaber, Danielle , Coppolla, Giovanni, Bordelon, Yvette , Dickerson, Brad C., Fagan, Anne M. , Fields, Julie A. , Forsberg, Leah K. , Galasko, Doug, Gavrilova, Ralitza H. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Graff‐Radford, Jonathan, Grant, Ian , Heuer, Hilary W. , Huey, Edward D. , Kornak, John , Ljubenkov, Peter A. , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Miyagawa, Toji , Onyike, Chiadi U. , Pedraza, Otto , Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Ritter, Aaron, Savica, Rodolfo , Toga, Arthur W. , Weıntraub, Sandra , Boxer, Adam L. , Rosen, Howard J. , Staffaroni, Adam M. , Hall, Matthew, Appleby, Brian S. , Botha, Hugo , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Fong, Jamie , Foroud, Tatiana , Goldman, Jill , Graff‐Radford, Jonathan , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Irwin, David J. , Jones, David T. , Kantarci, Kejal , Kremers, Walter K. , Lapid, Maria I. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , McMillan, Corey T. , Miller, Bruce L. , Pascual, Belén , Rexach, Jessica E. , Roberson, Erik D. , Rojas, Julio C. , Seeley, William W. , Tartaglia, Maria Carmela , Wong, Bonnie , Wszołek, Zbigniew K. , VandeVrede, Lawren , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S7 | Pages: No page available

10.1002/alz.050692 Get It

AbstractBackgroundUp to 30% of frontotemporal dementia (FTD) cases are due to known pathogenic mutations (f‐FTD). Little is known about the factors that predict who will choose to learn their results. Upcoming clinical trials in f‐FTD may require disclosure prior to enrollment, even before symptom onset, and thus characterizing this sample is important. Furthermore, understanding the mood impacts of genetic disclosure may guide genetic counseling practice.MethodF‐FTD participants (n=568) from families with a known pathogenic mutation (MAPT, C9orf72, GRN) were enrolled through the ARTFL/LEFFTDS Longitudinal FTD Study (ALLFTD) and provided the opportunity for disclosure. Independent‐sample t‐tests compared demographic and psychosocial factors between participants who did and did not receive their results. In participants who were asymptomatic at baseline and follow up (n=199,177 with follow‐up), linear mixed effects modeling was used to investigate pre‐ to post‐disclosure changes in the 15‐item Geriatric Depression Scale (GDS).ResultOf participants from families with a known pathogenic genetic mutation, 47% received genetic disclosure. Of the asymptomatic subset (n=386), 36% know their mutation status. Of these asymptomatic learners, 46% received disclosure through the study, and the remainder learned their genetic status prior to study enrollment. None of the analyzed demographic or psychosocial factors (i.e., sex, age, education, having children) differed between learners and non‐learners (p’s > 0.05). In the longitudinal analysis of asymptomatic participants, learners showed a pre‐ to post‐increase of 0.31 GDS points/year (95%CI: ‐0.08, 0.69, p = 0.12), whereas non‐learners showed a slight decline (‐0.15 points/year, 95%CI: ‐0.36, 0.06, p = 0.16). This difference between slopes was statistically significant (0.46, 95%CI: 0.02, 0.89, p=0.04) but represents a small clinical effect. In asymptomatic learners, slopes did not differ based on mutation status (0.28, 95%CI: ‐0.66, 1.20, p=0.55). Conclusions were based on the estimates and full range of confidence intervals.ConclusionThe majority of asymptomatic research participants do not know their genetic status, which will be a consideration for clinical trials that require disclosure. No considered demographic factors were strongly associated with the decision to receive disclosure. The findings suggest that disclosure in asymptomatic participants has minimal impact on depressive symptoms regardless of genetic results.
Gearing up for the future: Exploring facilitators and barriers to inform clinical trial design in frontotemporal lobar degeneration
Banga, Yasmin B, Lai, Yujung, Kim, Priscilla , Boxer, Adam L. , Rosen, Howard J. , Forsberg, Leah K. , Heuer, Hilary W. , Brushaber, Danielle , Bordelon, Yvette , Dickerson, Brad C., Dickinson, Susan, Faber, Kelley , Fagan, Anne M. , Fields, Julie A. , Fishman, Ann, Galasko, Doug, Gavrilova, Ralitza H. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Jonathan, Graff‐Radford, Neill R. , Grant, Ian , Huey, Edward D. , Karydas, Anna M., Kaufer, Daniel , Kramer, Joel H. , Kornak, John , Lagone, Emma, Ljubenkov, Peter A. , Lucente, Diane , Mackenzie, Ian R. , Manoochehri, Masood , Masdeu, Joseph C. , McGinnis, Scott, Mendez, Mario F, Miyagawa, Toji , Nelson, K. , Onyike, Chiadi U. , Pantelyat, Alex, Pearlman, Rodney , Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Ritter, Aaron, Sabbagh, Marwan N. , Salmon, David P. , Savica, Rodolfo , Staffaroni, Adam M. , Syrjanen, Jeremy A. , Tatton, Nadine , Taylor, Jack C. , Weıntraub, Sandra , Wheaton, Diana, Wong, Benjamin , Boeve, Bradley F. , Appleby, Brian S. , Biernacka, Joanna M. , Botha, Hugo , Bozoki, Andrea C , Brannelly, Patrick , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Foroud, Tatiana , Gendron, Tania F. , Goldman, Jill , Graff‐Radford, Jonathan , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Irwin, David J. , Jones, David T. , Kantarci, Kejal , Knopman, David S. , Kremers, Walter K. , Kukull, Walter A. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , Mendez, Mario F, Miller, Bruce L. , Nelson, Kevin M, Pascual, Belén , Pottier, Cyril , Rexach, Jessica E. , Roberson, Erik D. , Rojas, Julio C. , Seeley, William W. , Tartaglia, Maria Carmela , Toga, Arthur W. , Wszołek, Zbigniew K.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S7 | Pages: No page available

10.1002/alz.052495 Get It

AbstractBackgroundFrontotemporal lobar degeneration (FTLD) refers to a group of neurodegenerative conditions, affecting the frontal and/or temporal lobes. Ongoing research has provided insight into developing clinical trials for FTLD and key clinical measures such as structural MRI. To inform clinical trial design and optimize participation, it is imperative to explore facilitators and barriers for potential candidates.ObjectiveThe objective of this study is to explore facilitators and barriers to participating in future clinical trials for FTLD.MethodsAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) are observational studies focused on characterizing FTLD syndromes in preparation for clinical trials. The 584 participants enrolled across 18 research sites in the United States and Canada completed a survey assessing interest in clinical trial participation.Results29% of respondents self‐reported as patients (63±10 years), 26% self‐reported as caregivers answering on behalf of patients (65±10 years), and 45% self‐reported as healthy but at risk for FTLD (48±14 years). Travel reimbursement was the most common factor reported to positively influence participation (≧66%), with the healthy but at risk group showing the strongest endorsement (83%). Cost and time involved in travel were possible barriers for about half of the patients (48%) and healthy but at risk respondents (53%). The respondents value receiving feedback on the study findings (≧80%) and being informed of their individual disease progression (≧75%). Particularly, keeping participation confidential was very important for the healthy but at risk group (62%). In regard to research assessments, most participants demonstrated a high interest in physical and neurological exams at a research center (≧87%) whereas only half were interested in doing more invasive procedures such as the lumbar puncture (≧52%). Overall, respondents showed a positive attitude and support for research participation (≧77%) and trusted that their health information would remain confidential in a clinical trial (≧53%).ConclusionsFavorable attitudes and interest towards medical research exist among participants. To optimize participation, clinical trials should allocate funding for travel and involve participants in feedback about study results and their disease progression. Alternatives to invasive assessments may increase participation.
Timely Turnaround: A Humble Request to Employers
Kandi, Lyndsay A., Howard, Michael A., Casey, William J., Song, David H., Teven, Chad M., Kandi, Lyndsay A. , Howard, Michael A., Casey, William J., Song, David H., Teven, Chad M.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | January 26, 2022 | Volume: 10 | Issue: 1 | Pages: e4070

10.1097/gox.0000000000004070 | PMID 35186627 Get It

Surgical Management of Sacral Schwannomas: A 21-Year Mayo Clinic Experience and Comparative Literature Analysis
Ghaith, Abdul-Karim, Rush, Deja, Jarrah, R. Al, Alexander, Yohan, Zamanian, Cameron , Atkinson, John L. D., Yaszemski, Michael J. , Krauss, William E. , Spinner, Robert J. , Bydon, Mohamad , Mualem, William , Jarrah, Ryan

Mayo Clinic

No container title available | January 21, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1274638/v1 Get It

Abstract Introduction: Sacral and presacral schwannomas are rare and account for a minority of spinal schwannomas. We aim to present our institution’s experience surgically treating sacral schwannomas over twenty-one years. Additionally, we assess the literature for surgical cases of sacral schwannomas to compare tumor characteristics and outcomes following resection.Methods: Data on demographics, presenting symptoms, lesion characteristics, surgical management, and outcomes were collected for 27 patients treated surgically for sacral or presacral schwannoma between 1997 and 2018 at all Mayo Clinic locations and compared to those of patients found in the literature. Results: We identified 31 studies in the literature containing 93 patients with sacral schwannoma treated surgically. Our patients and those in the literature experienced similar symptoms, with the most common symptom being pain and the least common being sexual dysfunction, and age at diagnosis. Most of our patients (59.3%) reported full recovery from preoperative symptoms, while a minority reported a partial recovery (33.3%) and no recovery (11.1%). A smaller percentage of patients found in the literature experienced full recovery (31.9%) and partial recovery (29.8%) but also no recovery (1.1%). Our patients experienced fewer complications (14.8% versus 25.5%).Conclusion: Outcomes of patients with sacral or presacral schwannomas vary based on patient demographics, tumor characteristics, symptoms, and surgical treatment. Among the range of symptoms experienced by these patients, the most common is pain. Prognosis improves and overall survival rate is high when the surgical approach towards sacral schwannomas is prepared and executed appropriately.